Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-01-21Clinical Trial Update: Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b [Phase 2]
A Phase 2 trial evaluating bemarituzumab in combination with FLOT chemotherapy for perioperative treatment of FGFR2b-overexpressing gastric/…
-
CLINICAL_TRIALS withdrawal · 2025-12-26Clinical Trial Update: Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma [Phase 2]
A Phase 2 trial of zimberelimab plus domvanalimab in stomach and gastroesophageal junction adenocarcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-30Clinical Trial Update: A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors [Phase 1, Phase 2]
The Phase 1/2 trial of AB-201 for HER2-positive solid tumors has been withdrawn, with the study status updated to withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-08Clinical Trial Update: Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
A clinical trial evaluating circulating tumor DNA in locally advanced esophageal and gastroesophageal junction adenocarcinoma has been withd…
-
CLINICAL_TRIALS withdrawal · 2025-02-07Clinical Trial Update: Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers [Phase 1]
A Phase 1 neoadjuvant therapy trial for gastroesophageal junction and gastric cancers has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-01-24Clinical Trial Update: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 [Phase 1]
The Phase 1 trial of AB-201 for breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-12-16Clinical Trial Update: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension [Phase 3]
A Phase 3 trial (MK-3475-859/KEYNOTE-859) evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric/GEJ adenoca…
-
CLINICAL_TRIALS withdrawal · 2018-07-13Clinical Trial Update: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach [Phase 2]
This Phase 2 trial evaluating perioperative mFOLFOX6 plus pembrolizumab for potentially resectable gastroesophageal junction and stomach ade…